Humana Stock Rating Reaffirmed by Zacks (HUM)
Humana (NYSE:HUM)‘s stock had its “neutral” rating restated by Zacks in a research report issued to clients and investors on Thursday. They currently have a $131.00 target price on the stock. Zacks‘s price target would suggest a potential upside of 4.92% from the stock’s previous close.
Zacks’ analyst wrote, “Humana’s strength lies in its strong Medicare business, expansion of business platform and stable credit ratings. However, rising expenses, overhang of litigations, competitive pressure and high debt levels are partial setbacks. Although Humana’s first quarter earnings surpassed the Zacks Consensus Estimate, it declined year over year due to higher expense and effects of sequestration on the Medicare business. The dependence on Medicare Advantage plans and adverse impact of healthcare reform raise operational risks. Humana needs to follow prudent expense management and focus on growth through acquisitions and diversification of its earning sources to attract long-term investors. We maintain our Neutral recommendation on the stock.”
Humana (NYSE:HUM) traded up 1.18% during mid-day trading on Thursday, hitting $126.33. 269,642 shares of the company’s stock traded hands. Humana has a 52-week low of $82.14 and a 52-week high of $127.17. The stock has a 50-day moving average of $120.9 and a 200-day moving average of $109.1. The company has a market cap of $19.554 billion and a P/E ratio of 17.56.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $2.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.94 by $0.41. During the same quarter in the prior year, the company posted $2.69 earnings per share. On average, analysts predict that Humana will post $7.81 earnings per share for the current fiscal year.
HUM has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. They now have a $155.00 price target on the stock. Separately, analysts at Stifel upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. They now have a $155.00 price target on the stock. Finally, analysts at Leerink Swann reiterated an “outperform” rating on shares of Humana in a research note on Friday, May 23rd. They now have a $140.00 price target on the stock, up previously from $135.00. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $125.80.
Humana Inc (NYSE:HUM) is a health care company.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.